Multicenter phase Ib-II dose-escalation of trabectedin (Yondelis) in combination with oxaliplatin in patients with cancer pretreated advanced ovarian. [Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis) en association avec l'oxaliplatine chez des patientes atteintes d'un cancer de l'ovaire avancé prétraité.]

Trial Profile

Multicenter phase Ib-II dose-escalation of trabectedin (Yondelis) in combination with oxaliplatin in patients with cancer pretreated advanced ovarian. [Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis) en association avec l'oxaliplatine chez des patientes atteintes d'un cancer de l'ovaire avancé prétraité.]

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2012

At a glance

  • Drugs Oxaliplatin; Trabectedin
  • Indications Ovarian cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors PharmaMar
  • Most Recent Events

    • 14 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top